Skip to main content

Table 1 Comparison of study population according to COVID19 related status at the end of study period

From: COVID19-related and all-cause mortality risk among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection: a population-based cohort study in Southern Catalonia, Spain, March–June 2020

COVID19 related status

COVID19

Nonrelated

(Healthy)

N = 74,687

COVID19

Excluded

(PCR-)

N = 3577

COVID19

Suspected

(without PCR)

N = 283

COVID19

Confirmed

(PCR+)

N = 536

P-value

Characteristic

n (%)

n (%)

n (%)

n (%)

Sociodemographical

Age group

  50–64 yrs

40,799 (54.6)

1492 (41.7)

216 (76.3)

177 (33.0)

< 0.001

 65–79 yrs

24,638 (33.0)

1186 (33.2)

52 (18.4)

137 (25.6)

  ≥ 80 yrs

9250 (12.4)

899 (25.1)

15 (5.3)

222 (41.4)

Sex

 Men

35,575 (47.6)

1701 (47.6)

115 (40.6)

235 (43.8)

0.036

 Women

39,112 (52.4)

1876 (52.4)

168 (59.4)

301 (56.2)

Community-dwelling

73,870 (98.9)

3174 (88.7)

280 (98.9)

345 (64.4)

< 0.001

Nursing-home residence

817 (1.1)

403 (11.3)

3 (1.1)

191 (35.6)

Comorbidities

Neurological disease

1935 (2.6)

293 (8.2)

10 (3.5)

79 (14.7)

< 0.001

Renal disease

3982 (5.3)

420 (11.7)

9 (3.2)

65 (12.1)

< 0.001

Cancer

5995 (8.0)

549 (15.3)

19 (6.7)

67 (12.5)

< 0.001

Rheumatic disease

804 (1.1)

57 (1.6)

4 (1.4)

7 (1.3)

0.032

Inflammatory bowel disease

497 (0.7)

27 (0.8)

2 (0.7)

6 (1.1)

0.567

Respiratory disease

6592 (8.8)

567 (15.9)

33 (11.7)

80 (14.9)

< 0.001

Cardiac disease

12,232 (16.4)

1016 (28.4)

34 (12.0)

153 (28.5)

< 0.001

Atrial fibrillation

3317 (4.4)

392 (11.0)

7 (2.5)

70 (13.1)

< 0.001

Liver disease

1338 (1.8)

110 (3.1)

6 (2.1)

11 (2.1)

< 0.001

Diabetes

12,322 (16.5)

838 (23.4)

31 (11.0)

126 (23.5)

< 0.001

Hypertension

32,604 (43.7)

1937 (54.2)

114 (40.3)

290 (54.1)

< 0.001

Hypercholesterolemia

25,638 (34.3)

1398 (39.1)

97 (34.3)

181 (33.8)

< 0.001

Obesity

20,468 (27.4)

1013 (28.3)

62 (21.9)

135 (25.2)

0.068

Smoking

12,074 (16.2)

591 (16.5)

44 (15.5)

41 (7.6)

< 0.001

Alcoholism

1644 (2.2)

134 (3.7)

7 (2.5)

11 (2.1)

< 0.001

Chronic medications use

Diuretics

7586 (10.2)

731 (20.4)

25 (8.8)

139 (25.9)

< 0.001

Beta blockers

8817 (11.8)

632 (17.7)

35 (12.4)

87 (16.2)

< 0.001

ACEIs

15,374 (20.6)

872 (24.4)

59 (20.8)

114 (21.3)

< 0.001

ARBs

8317 (11.1)

471 (13.2)

27 (9.5)

54 (10.1)

0.001

Calcium channel blockers

5990 (8.0)

420 (11.7)

16 (5.7)

64 (11.9)

< 0.001

Statins

15,063 (20.2)

936 (26.2)

44 (15.5)

91 (17.0)

< 0.001

Oral anticoagulants

3461 (4.6)

385 (10.8)

8 (2.8)

58 (10.8)

< 0.001

Antiplatelet drugs

8344 (11.2)

676 (18.9)

26 (9.2)

108 (20.1)

< 0.001

Insulin

2726 (3.6)

271 (7.6)

2 (0.7)

43 (8.0)

< 0.001

Oral antidiabetic drugs

9855 (13.2)

623 (17.4)

22 (7.8)

85 (15.9)

< 0.001

Inhaled respiratory drugs

5628 (7.5)

552 (15.4)

36 (12.7)

77 (14.4)

< 0.001

Antineoplastic agents

104 (0.1)

12 (0.3)

0 (0.0)

0 (0.0)

0.017

Systemic corticosteroids

1105 (1.5)

130 (3.6)

7 (2.5)

10 (1.9)

< 0.001

NSADs

4079 (5.5)

191 (5.3)

30 (10.6)

21 (3.9)

0.001

Chloroquine

154 (0.2)

11 (0.3)

2 (0.7)

1 (0.2)

0.176

Antihistamines

3085 (4.1)

152 (4.2)

12 (4.2)

15 (2.8)

0.469

Proton-Pump Inhibitors

16,254 (21.8)

1423 (39.8)

71 (25.1)

183 (34.1)

< 0.001

Benzodiazepines

12,026 (16.1)

819 (22.9)

75 (26.5)

126 (23.5)

< 0.001

Vaccination’s history

Flu vaccine in prior autumn

20,838 (27.9)

1449 (40.5)

61 (21.6)

258 (48.1)

< 0.001

PPV23

24,189 (32.4)

1666 (46.6)

56 (19.8)

272 (50.7)

< 0.001

PCV13

1005 (1.3)

108 (3.0)

8 (2.8)

18 (3.4)

< 0.001

Tetanus

47,761 (63.9)

2507 (70.1)

187 (66.1)

344 (64.2)

< 0.001

  1. P-values were calculated by Chi-squared or Fisher’s test as appropriate